Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.
The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).
16 United States sites
3 Canada sites
18 Years - 50 Years
Phase 1/Phase 2
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
49 United States sites
5 France sites
5 Spain sites
4 Greece sites
4 Italy sites
4 United Kingdom sites
3 Canada sites
2 Lebanon sites
2 Germany sites
12 Years - 65 Years
Phase 2/Phase 3
This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.
1 United States site
8 Years - 21 Years
Hemoglobin SS
Phase 4
The purpose of the study is to assess the safety and tolerability of AG-946 in healthy volunteers after oral administration of single ascending doses (SAD) and multiple ascending doses (MAD) of AG-946 over 14 or up to 28 days of dosing, and to identify a range of doses that are safe and pharmacologically active in participants with sickle cell disease.
8 United States sites
2 Spain sites
1 Denmark site
18 Years - 70 Years
Phase 1
Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which delivers oxygen throughout the body.
4 United States sites
1 Canada site
> 18 Years
Phase 1/Phase 2
This study is evaluating a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle cell disease.
4 United States sites
1 Italy site
2 Years - 40 Years
HbSS, HbSC
Phase 1/Phase 2
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
18 United States sites
1 United Kingdom site
1 France site
> 18 Years
Phase 3
This study aims to enroll 58 pre-adolescent (<13 years) pediatric participants with sickle cell disease (SCD) who have a pre-adolescent sibling bone marrow donor.
11 United States sites
2 Years - 13 Years
HbSS
Phase 2
This will be a descriptive cohort study of intranasal ketamine as the initial analgesic for children with sickle cell disease who present to the pediatric emergency department with vaso-occlusive crisis and are awaiting intravenous line placement.
2 United States sites
3 Years - 25 Years
Hemoglobin SS
Phase 3
The ASCENT Trial is a single arm, multi-center, phase II study.
9 United States sites
< 20 Years
Phase 2
